RecruitingNot ApplicableNCT05830929
Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation for Female Cancer Patients
Sponsor
Chinese University of Hong Kong
Enrollment
100 participants
Start Date
Aug 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Ovarian Tissue Cryopreservation will be provided to cancer patients to allow them to have their fertility preserved.
Eligibility
Sex: FEMALEMin Age: 1 MonthMax Age: 35 Years
Inclusion Criteria3
- Patients aged from 0-35 years old and diagnosed with cancer e.g., leukaemia, myeloproliferative or myelodysplastic diseases, lymphoma, bone tumours, neurological neoplasms and sarcoma, Paediatric bone marrow transplant patients
- Patients with any illness or who will undergo any type of treatment that may cause irreversible damage to their fertility, such as extensive abdominal surgery, high toxicity medication and treatments;
- Patients suffering from hormone-sensitive malignancies who will undergo medical treatment, such as radiotherapy and chemotherapy that is liable to damage their ovaries and deter them from conception in the future.
Exclusion Criteria5
- Patients with no anticipated oncologic therapies
- Patients who are pregnant
- Children with one ovary
- Children deemed high risk for perioperative complications
- Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)
Interventions
PROCEDUREOvarian tissue freezing and subsequent auto-transplantation after thawing
Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05830929
Related Trials
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location
Anatomical-Clinical Base of Adenocarcinoma Pancreatic
NCT061283438 locations
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT074696831 location
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
NCT0407530518 locations
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
NCT0688461819 locations